Introducing Hamlet BioPharma to investors
Hamlet BioPharma the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections today launches the new website introducing Hamlet BioPharma, providing a first overview of the company, recent transactions and the main projects.
A merger of HAMLET Pharma and SelectImmune Pharma was formally decided on May 17th, 2023. The decisions were taken by extra general assemblies in the respective companies. The transaction also includes the acquisition of a tuberculosis project and a collaboration agreement with Linnane Pharma. The formal process of the merger is being initiated and the process of establishing Hamlet BioPharma is estimated to complete in August.
For more information, please see www.hamletbiopharma.com
For more information, contact
Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49, Catharina.svanborg@med.lu.se
Martin Erixon, CEO of Hamlet Pharma, +46-733 00 43 77, martin.erixon@hamletpharma.com
About Hamlet Pharma AB
Hamlet Pharma, whose shares are listed on the Spotlight Stock Market, is a company engaged in drug development based on a tumor-killing protein-lipid complex, HAMLET, formed from two natural and harmless molecules found in breast milk. The development aims to produce preparations that are primarily to be used for the treatment and prevention of cancer diseases. Alpha1H is the synthetic variant of HAMLET, which enabled the development of the substance for clinical trials. Hamlet Pharma is conducting clinical development work with Alpha1H in patients with bladder cancer, a difficult to cure and costly form of cancer. The company is also developing Alpha1H for the treatment of brain tumors and is currently conducting a Technical Evaluation of BAMLET and intends, if the evaluation turns out positive, to create conditions suitable for the continued development of BAMLET.